Follow the people · Insider
Fred Aslan
Fred Aslan files insider transactions with the SEC as a chief executive officer of Artiva Biotherapeutics (ARTV). We hold 2 disclosed purchases and sales filed since 22 July 2024, 1 of them in the last 90 days.
- Files forARTV
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure4 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 July 2024 — 3 September 2026Chief Executive Officer · Artiva Biotherapeutics (ARTV)23 Form 4 lines · source: SEC Form 4
Everything they disclosed
23 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 61,888 shares of Artiva BiotherapeuticsSEC Form 44 September 2026Common Stock · traded 3 September 2026 · filed 4 September 2026
- ▼ sold on the open market 27,116 shares of Artiva BiotherapeuticsSEC Form 419 May 2026Common Stock · traded 19 May 2026 · filed 19 May 2026
- was granted 366,850 shares of Artiva BiotherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- had shares withheld for tax on 14,600 shares of Artiva BiotherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- was granted 366,850 shares of Artiva BiotherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- had shares withheld for tax on 14,600 shares of Artiva BiotherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- ▼ sold on the open market 3,187 shares of Artiva BiotherapeuticsSEC Form 415 December 2025Common Stock · traded 15 December 2025 · filed 15 December 2025
- returned to the issuer 100,577 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- returned to the issuer 51,463 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- returned to the issuer 257,319 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- returned to the issuer 26,450 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- returned to the issuer 113,999 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- returned to the issuer 319,331 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 412 December 2025Employee Stock Option (Right to Buy) · traded 12 December 2025 · filed 12 December 2025
- was granted 869,136 shares of Artiva BiotherapeuticsSEC Form 412 December 2025Common Stock · traded 12 December 2025 · filed 12 December 2025
- had shares withheld for tax on 6,347 shares of Artiva BiotherapeuticsSEC Form 417 November 2025Common Stock · traded 15 November 2025 · filed 17 November 2025
- ▼ sold on the open market 6,375 shares of Artiva BiotherapeuticsSEC Form 417 November 2025Common Stock · traded 17 November 2025 · filed 17 November 2025
- ▼ sold on the open market 25,500 shares of Artiva BiotherapeuticsSEC Form 417 October 2025Common Stock · traded 17 October 2025 · filed 17 October 2025
- had shares withheld for tax on 4,472 shares of Artiva BiotherapeuticsSEC Form 418 August 2025Common Stock · traded 15 May 2025 · filed 18 August 2025
- ▼ sold on the open market 25,500 shares of Artiva BiotherapeuticsSEC Form 418 August 2025Common Stock · traded 15 August 2025 · filed 18 August 2025
- had shares withheld for tax on 4,472 shares of Artiva BiotherapeuticsSEC Form 418 August 2025Common Stock · traded 15 August 2025 · filed 18 August 2025
- was granted 200,000 shares of Artiva BiotherapeuticsSEC Form 47 March 2025Common Stock · traded 5 March 2025 · filed 7 March 2025
- was granted 343,811 shares of Artiva Biotherapeutics (a derivative holding)SEC Form 422 July 2024Employee Stock Option (Right to Buy) · traded 18 July 2024 · filed 22 July 2024
- was granted 228,905 shares of Artiva BiotherapeuticsSEC Form 422 July 2024Common Stock · traded 22 July 2024 · filed 22 July 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.